Ilorasertib hydrochloride, also known as ABT-348 hydrochloride, is primarily investigated for its potential in cancer therapy. It functions as an Aurora kinase inhibitor, targeting and inhibiting the activity of Aurora kinases, which are enzymes crucial for cell division and proliferation. By disrupting these kinases, ilorasertib hydrochloride can hinder the growth and survival of cancer cells, particularly in tumors that rely on Aurora kinase activity for their progression. This compound has been studied in clinical trials for its efficacy in treating various types of cancers, including solid tumors and hematologic malignancies. Its application is particularly relevant in cases where traditional therapies have failed or where cancers exhibit resistance to conventional treatments. Researchers are also exploring its use in combination with other anticancer agents to enhance therapeutic outcomes and overcome drug resistance. Additionally, ilorasertib hydrochloride's role in targeting specific molecular pathways makes it a valuable tool in precision medicine, allowing for tailored treatments based on the genetic and molecular profile of individual tumors. Ongoing research continues to evaluate its safety, efficacy, and potential as a targeted therapy in oncology.